Jangir Exports

Jangir Exports is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2017, the company is headquartered in New Delhi, India. It operates as a proprietorship firm under the leadership of CEO Ram Lal Jangir. The company has a workforce of approximately 26 to 50 employees. Jangir Exports' registered address is A-39, A-40, 1st Floor, Ambey Garden, 60 Foot Road, Libaspur, GT Karnal Road, AG Block, G, New Delhi-110042, Delhi, India.

The company's Import Export Code (IEC) is 0500029733, and it is registered under GST No. 07AAGPJ3994E1ZL. Jangir Exports has an annual turnover ranging between 1.5 to 5 crore INR. The official website of Jangir Exports is www.jangircompany.in.

Jangir Exports operates manufacturing facilities in New Delhi, India. The company specializes in the production of Ayurvedic and herbal pharmaceutical formulations, focusing on tablets, capsules, syrups, and injections. Specific details regarding the manufacturing plant locations, capacities, and certifications are not publicly disclosed. However, the company emphasizes its commitment to quality and compliance with international standards.

The leadership team at Jangir Exports is headed by CEO Ram Lal Jangir, who also serves as the proprietor of the company. The company's registered address is A-39, A-40, 1st Floor, Ambey Garden, 60 Foot Road, Libaspur, GT Karnal Road, AG Block, G, New Delhi-110042, Delhi, India. Specific information regarding other key executives, such as the CFO or other senior management members, is not publicly available.

Jangir Exports primarily focuses on exporting Ayurvedic and herbal pharmaceutical formulations to various international markets. The company's total export value is $696,000 USD, with 914 shipments across three products in the Ayurvedic & Herbal Products category. The top three products exported are Herbal formulations ($641,000 USD), Kwatha ($50,000 USD), and Gutika ($5,000 USD). The company holds a 3.4% market share in Herbal formulations, a 9.4% market share in Kwatha, and a 3.9% market share in Gutika. Specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly disclosed.

Jangir Exports has a presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and herbal products aligns with the growing demand for natural and traditional medicines in these regions. While specific details regarding WHO prequalification and other regulatory approvals are not publicly available, the company's export activities suggest an effort to meet international standards and gain access to these markets.

Jangir Exports demonstrates a diversified geographic strategy by exporting its Ayurvedic and herbal pharmaceutical formulations to various international markets. The company's export data indicates shipments to multiple countries, reflecting a broad market reach. However, the company's portfolio concentration is high, with the top three products accounting for 100% of the export value. This suggests a potential risk if demand for these specific products declines. The company's strategic direction appears to focus on leveraging the growing global interest in Ayurvedic and herbal products.

Specific information regarding Jangir Exports' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate shipments to the United States, suggesting that it may not currently have FDA approvals or registrations. This could be due to the nature of the products (Ayurvedic and herbal formulations) and the regulatory requirements for such products in the US market.

Jangir Exports' export data does not provide specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's focus on Ayurvedic and herbal products may require adherence to specific international standards; however, without publicly available certifications, it is challenging to assess the company's compliance with these standards.

Jangir Exports operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's registered address is A-39, A-40, 1st Floor, Ambey Garden, 60 Foot Road, Libaspur, GT Karnal Road, AG Block, G, New Delhi-110042, Delhi, India. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

There is no publicly available information regarding Form 483 observations, warning letters, or import alerts related to Jangir Exports. The company's export data does not indicate any regulatory issues or actions in the markets it serves.

Jangir Exports operates in the Ayurvedic and herbal pharmaceutical sector, a niche market with several key players. While specific competitors are not identified in the available data, the company's focus on Ayurvedic and herbal formulations positions it in a competitive landscape that includes both domestic and international manufacturers. The company's export data indicates a total export value of $696,000 USD, with 914 shipments across three products, suggesting a moderate market presence.

Jangir Exports' key differentiators include its specialization in Ayurvedic and herbal pharmaceutical formulations, catering to the growing global demand for natural and traditional medicines. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, allows it to offer ready-to-use products that meet international standards. However, the company's portfolio concentration, with the top three products accounting for 100% of the export value, may limit its ability to diversify and adapt to changing market demands.

Jangir Exports' current strategic direction focuses on exporting Ayurvedic and herbal pharmaceutical formulations to international markets. The company's export data indicates shipments to various countries, reflecting a broad market reach. However, the high portfolio concentration suggests a need for diversification to mitigate potential risks. The company's future outlook may involve expanding its product portfolio, obtaining international certifications, and exploring new markets to strengthen its competitive position.

Jangir Exports has a total export value of $696,000 USD, with 914 shipments across three products in the Ayurvedic & Herbal Products category. The top three products exported are Herbal formulations ($641,000 USD), Kwatha ($50,000 USD), and Gutika ($5,000 USD). The company holds a 3.4% market share in Herbal formulations, a 9.4% market share in Kwatha, and a 3.9% market share in Gutika. The company's export data indicates a moderate market presence, with a focus on Ayurvedic and herbal products. However, the high portfolio concentration suggests a need for diversification to enhance reliability and reduce dependency on a limited product range.

Importers should verify the following certifications when considering Jangir Exports as a supplier:

• FDA Registration: To ensure compliance with US regulatory standards, verify the company's FDA facility registration status. This can be done by searching the FDA's Establishment Registration & Device Listing database.

• WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices, request a copy of the WHO-GMP certificate from the company.

• EU GMP Certification: For compliance with European Union Good Manufacturing Practices, obtain the EU GMP certificate from the company.

• ISO Certification: To assess the company's quality management systems, request copies of relevant ISO certifications.

When conducting due diligence on Jangir Exports, consider the following steps:

• Verify Certifications: Ensure the company holds relevant certifications, such as FDA registration, WHO-GMP, EU GMP, and ISO.

• Assess Product Portfolio: Evaluate the diversity of the company's product offerings to understand potential risks associated with portfolio concentration.

• Review Regulatory Compliance: Confirm the company's compliance with regulatory requirements in target markets, including obtaining necessary approvals